NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-HL-22-014 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seeks highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions to widely-recognized issues in the development of safe and effective RM therapies. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance into clinical trials. This FOA seeks Phase I and beyond clinical trial applications that present a strong scientific rationale for the proposed clinical trial and a comprehensive scientific and operational plan. Trials must be relevant to the research mission of one or more participating NIH Institutes and Centers and meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applications are expected to include plans for project management, participant recruitment and retention, performance milestones, conduct of the trial, and dissemination of results. Before the time of award and if applicable, successful applicants must obtain an Investigational New Drug (IND) authorization or Investigational New Device Exemption (IDE) approval to administer the product to humans. Successful applicants proposing the use of adult stem cells as a clinical intervention will be asked to make available representative samples of the source stem cell and clinical-grade stem cell-derived product for in-depth and independ
Notice NOT-HS-21-017 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-21-025 from the NIH Guide for Grants and Contracts. The purpose of the FIRST Cohort is to transform culture at NIH-funded extramural institutions by building a self-reinforcing community of scientists committed to diversity and inclusive excellence (defined below). Implementing and sustaining cultures of inclusive excellence within the program has the potential to be transformational for biomedical research at the awardee institutions and beyond. This community will be built through recruitment of faculty who are competitive for an advertised research tenure-track or equivalent faculty position (positions must be at the Assistant Professor (or equivalent) level), have not held a position at this level, and have demonstrated strong commitment to promoting diversity and inclusive excellence.
Network of the National Library of Medicine All of Us Program Center (U24) (Clinical Trial Optional)
Funding Opportunity RFA-LM-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement (U24) applications for the Network of the National Library of Medicine (NNLM) All of Us Program Center (NACP). The mission of the NNLM is to provide U.S. health professionals, researchers, public health workforce, educators, and the public with equal access to biomedical and health information resources and data. NNLMs main goals are to work through libraries and other members to support a highly-trained workforce for biomedical and health information resources and data, improve health literacy, and increase health equity through information. The NNLM All of Us National Program Center (NAPC) will serve as the coordinating center and be responsible for the engagement, programs, partnerships, activities, and training offered by NNLM in support of the NIH All of Us Research Program. All of Us is working to improve health care through research by building a diverse database that can inform thousands of studies on a variety of health conditions. The NACP will continue to improve and innovate in two main functional areas: Training and Education, and Community Engagement. These two functional areas collaborate, coordinate, and cooperate to design, deliver, report, and evaluate innovative, responsive, and effective programs and services. They also work together to increase awareness about the NIH All of Us Research Program and to improve the health, digital, and related literacy skills that allow the general public to participate in long-term clinical research programs.
Funding Opportunity PAR-21-247 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.
Funding Opportunity PAR-21-274 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support the program "Cancer Target Discovery and Development (CTD2, pronounced cee-tee-dee-squared). CTD2 is focused on efforts that advance cancer research by bridging the knowledge gap between the large volumes of comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis. The primary purpose of CTD2 is to advance the following areas: Improving the understanding of how mutations in cancer-associated genes affect the protein activity (e.g., gain-of-function, loss-of-function, or neomorphic function) within the cellular pathway(s) they are part of and the cellular changes that result within the context of various tumors and the microenvironment; Identifying new molecular targets with the goal to understand their wiring mechanisms and how overcome innate and/or acquired resistance to therapies, particularly clinical resistance related to inter- and intra- tumor heterogeneity; and Developing efficient strategies to identify appropriate multiple targets and optimal combination of perturbagens (chemical or biological; immunotherapeutics being a prime example of the latter) with the potential to eliminate all cancer cells, despite their clonal heterogeneity and their surrounding microenvironment.
Funding Opportunity PAR-21-248 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune systemdevelopment patterns between two or more age groups- neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on ontogeny and development of pediatric immune system, from birth, transitioning into adolescence and adulthood with focus impact during pregnancy and post-natal period.
Funding Opportunity PAR-21-281 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites basic and/or methodological research projects that seek to illuminate or measure independent and interdependent health-related effects within dyads. For the purpose of this FOA, a dyad is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Both animal and human subjects research projects are welcome. Types of projects submitted under this FOA include but are not limited to, studies observational studies involving humans, or existing/synthesized datasets studies. Applications proposing studies that prospectively assign human participants to conditions meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024). Researchers proposing basic science experimental studies involving human participants (i.e., experimentally manipulate independent variables) should consider the companion FOA PAR-XX-XXX "Dyadic Interpersonal Processes and Biopsychosocial outcomes (R01 Basic Experimental Studies with Humans).
Funding Opportunity PAR-21-280 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites basic and/or methodological research projects that seek to illuminate or measure independent and interdependent health-related effects within dyads. For the purpose of this FOA, a dyad is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects that emanate from intra-dyadic phenomena. NIH considers such studies as prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024). Applications proposing studies using model animal research, observational studies involving humans, or existing/synthesized datasets should submit under the companion FOA PAR-XX-XXX " Dyadic interpersonal processes and biopsychosocial outcomes (R01 Clinical Trials Not Allowed).
Funding Opportunity RFA-HG-21-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.
Funding Opportunity RFA-HG-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.
Notice NOT-CA-21-092 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-145 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-21-050 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement solicits applications to establish the Antiviral Drug Discovery (AViDD) program of multidisciplinary Centers focused on discovery and development of antivirals against coronaviruses (CoVs) and select RNA viruses with pandemic potential. Through this program, NIAID will encourage the development of antivirals that are effective against multiple viruses, technologies that can be widely applied to improve classes of antivirals, and platforms that can reduce the time and cost of creating new antivirals.
Funding Opportunity RFA-DA-23-001 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support projects that further develop or exploit advances using in situ or in vivo imaging or related technologies to investigate HIV/SIV infection, latent reservoirs, the pathogenic consequences of HIV/SIV infection, or the effects of HIV/SIV or substance use disorder (SUD) therapies. Applicants may propose primate or human studies to investigate blood, lymphoid, or brain tissues.
Notice NOT-GM-21-054 from the NIH Guide for Grants and Contracts
Notice NOT-DE-21-008 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-157 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-149 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-239 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-755. The primary goal of the NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22) Program (hereafter abbreviated as the NIMH Career Transition K22 Program) is to provide support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research Programs (DIRP) to an independent research faculty position in the extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related fields